{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T18:37:54Z","timestamp":1789843074098,"version":"4.0.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100019412","name":"Bursa Uluda\u011f \u00dcniversitesi","doi-asserted-by":"publisher","award":["2023-18\/2"],"award-info":[{"award-number":["2023-18\/2"]}],"id":[{"id":"10.13039\/100019412","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.msard.2024.105850","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T20:56:18Z","timestamp":1725051378000},"page":"105850","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Effects of disease-modifying therapies on remyelination in multiple sclerosis; evaluation via visual evoked potential test"],"prefix":"10.1016","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5945-2317","authenticated-orcid":false,"given":"Furkan","family":"Saridas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farid","family":"Hojjati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanay","family":"Alizada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarra","family":"Lazrak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emine Rabia","family":"Koc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer Faruk","family":"Turan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.msard.2024.105850_bib0001","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3109\/01658107.2015.1074253","article-title":"Multifocal visual evoked potential (mfVEP) and pattern-reversal visual evoked potential changes in patients with visual pathway disorders: a case series","volume":"39","author":"Alshowaeir","year":"2015","journal-title":"Neuroophthalmology"},{"issue":"Pt 1","key":"10.1016\/j.msard.2024.105850_bib0002","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/brain\/awu335","article-title":"Vision and vision-related outcome measures in multiple sclerosis","volume":"138","author":"Balcer","year":"2015","journal-title":"Brain"},{"key":"10.1016\/j.msard.2024.105850_bib0003","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.cnp.2019.03.002","article-title":"The electrophysiological assessment of visual function in Multiple Sclerosis","volume":"4","author":"Barton","year":"2019","journal-title":"Clin. Neurophysiol. Pract."},{"issue":"2","key":"10.1016\/j.msard.2024.105850_bib0004","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1001\/jama.2018.20588","article-title":"Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis","volume":"321","author":"Brown","year":"2019","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.msard.2024.105850_bib0005","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S1474-4422(21)00179-4","article-title":"Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study","volume":"20","author":"Brown","year":"2021","journal-title":"Lancet Neurol."},{"issue":"Pt 3","key":"10.1016\/j.msard.2024.105850_bib0006","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1093\/brain\/124.3.468","article-title":"Long-term remyelination after optic neuritis: a 2-year visual evoked potential and psychophysical serial study","volume":"124","author":"Brusa","year":"2001","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.msard.2024.105850_bib0007","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s00415-019-09421-x","article-title":"Promoting remyelination in multiple sclerosis","volume":"268","author":"Cunniffe","year":"2021","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2024.105850_bib0008","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jneuroim.2015.08.004","article-title":"Impact of glatiramer acetate on paraclinical markers of neuroprotection in multiple sclerosis: a prospective observational clinical trial","volume":"287","author":"Ehling","year":"2015","journal-title":"J. Neuroimmunol."},{"issue":"1","key":"10.1016\/j.msard.2024.105850_bib0009","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.expneurol.2009.12.020","article-title":"Overcoming remyelination failure in multiple sclerosis and other myelin disorders","volume":"225","author":"Fancy","year":"2010","journal-title":"Exp. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2024.105850_bib0010","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nrneurol.2014.37","article-title":"Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis","volume":"10","author":"Friese","year":"2014","journal-title":"Nat. Rev. Neurol."},{"issue":"7","key":"10.1016\/j.msard.2024.105850_bib0011","doi-asserted-by":"crossref","first-page":"88","DOI":"10.17116\/jnevro202312307288","article-title":"[Characteristics and dynamics of pathological changes in visual evoked potentials in multiple sclerosis]","volume":"123","author":"Granatov","year":"2023","journal-title":"Zh. Nevrol. Psikhiatr. Im. S. S. Korsakova"},{"key":"10.1016\/j.msard.2024.105850_bib0012","first-page":"1409","article-title":"Eye disorders in patients with multiple sclerosis: natural history and management","volume":"4","author":"Graves","year":"2010","journal-title":"Clin. Ophthalmol."},{"issue":"10111","key":"10.1016\/j.msard.2024.105850_bib0013","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1016\/S0140-6736(17)32346-2","article-title":"Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial","volume":"390","author":"Green","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2024.105850_bib0014","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jns.2016.04.026","article-title":"Multimodal evoked potentials follow up in multiple sclerosis patients under fingolimod therapy","volume":"365","author":"Iodice","year":"2016","journal-title":"J. Neurol. Sci."},{"issue":"Pt 6","key":"10.1016\/j.msard.2024.105850_bib0015","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1093\/brain\/awn080","article-title":"Remyelination protects axons from demyelination-associated axon degeneration","volume":"131","author":"Irvine","year":"2008","journal-title":"Brain"},{"issue":"10127","key":"10.1016\/j.msard.2024.105850_bib0016","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","article-title":"Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study","volume":"391","author":"Kappos","year":"2018","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.msard.2024.105850_bib0017","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1111\/ene.13404","article-title":"Progression of retinal ganglion cell loss in multiple sclerosis is associated with new lesions in the optic radiations","volume":"24","author":"Klistorner","year":"2017","journal-title":"Eur. J. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2024.105850_bib0018","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/WNP.0000000000000757","article-title":"Latency of multifocal visual evoked potential in multiple sclerosis: a visual pathway biomarker for clinical trials of remyelinating therapies","volume":"38","author":"Klistorner","year":"2021","journal-title":"J. Clin. Neurophysiol."},{"key":"10.1016\/j.msard.2024.105850_bib0019","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.725187","article-title":"Role of multifocal visually evoked potential as a biomarker of demyelination, spontaneous remyelination, and myelin repair in multiple sclerosis","volume":"15","author":"Klistorner","year":"2021","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.msard.2024.105850_bib0020","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.3389\/fimmu.2018.03116","article-title":"Pathogenic mechanisms associated with different clinical courses of multiple sclerosis","volume":"9","author":"Lassmann","year":"2018","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.msard.2024.105850_bib0021","doi-asserted-by":"crossref","first-page":"e00703","DOI":"10.1002\/brb3.703","article-title":"Evoked potential changes in patients with Parkinson's disease","volume":"7","author":"Liu","year":"2017","journal-title":"Brain Behav."},{"issue":"4","key":"10.1016\/j.msard.2024.105850_bib0022","first-page":"251","article-title":"Influence of the metabolic control on latency values of visual evoked potentials (VEP) in patients with diabetes mellitus type 1","volume":"150","author":"Matanovic","year":"2012","journal-title":"Arch. Ital. Biol."},{"issue":"2\u20133","key":"10.1016\/j.msard.2024.105850_bib0023","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/BF02191555","article-title":"Treatment of multiple sclerosis with mitoxantrone","volume":"242","author":"Mauch","year":"1992","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"3","key":"10.1016\/j.msard.2024.105850_bib0024","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.msard.2024.105850_bib0025","first-page":"711","article-title":"[The effect of the disease duration on the changes of the visual evoked potentials and contrast sensitivity in multiple sclerosis]","volume":"65","author":"Murav'eva","year":"2015","journal-title":"Zh. Vyssh. Nerv. Deiat. Im. I. P. Pavlova"},{"key":"10.1016\/j.msard.2024.105850_bib0026","doi-asserted-by":"crossref","DOI":"10.1177\/1756286421997372","article-title":"Teriflunomide treatment is associated with optic nerve recovery in early multiple sclerosis","volume":"14","author":"Pfeuffer","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"1","key":"10.1016\/j.msard.2024.105850_bib0027","doi-asserted-by":"crossref","DOI":"10.1136\/bmjno-2023-000560","article-title":"Visual outcome measures in clinical trials of remyelinating drugs","volume":"6","author":"Riboni-Verri","year":"2024","journal-title":"BMJ Neurol. Open."},{"issue":"6","key":"10.1016\/j.msard.2024.105850_bib0028","doi-asserted-by":"crossref","first-page":"E252","DOI":"10.25011\/cim.v40i6.29126","article-title":"Pattern reversal visual evoked potentials in adults: variability with age","volume":"40","author":"Sawaya","year":"2017","journal-title":"Clin. Invest. Med."},{"issue":"1","key":"10.1016\/j.msard.2024.105850_bib0029","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1177\/1352458511415452","article-title":"Simvastatin improves final visual outcome in acute optic neuritis: a randomized study","volume":"18","author":"Tsakiri","year":"2012","journal-title":"Mult. Scler."},{"issue":"1\u20132","key":"10.1016\/j.msard.2024.105850_bib0030","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jns.2013.09.027","article-title":"Assessment of structural and functional visual outcomes in relapsing remitting multiple sclerosis with visual evoked potentials and optical coherence tomography","volume":"335","author":"Tugcu","year":"2013","journal-title":"J. Neurol. Sci."},{"issue":"3","key":"10.1016\/j.msard.2024.105850_bib0031","doi-asserted-by":"crossref","first-page":"471","DOI":"10.13075\/ijomeh.1896.00452","article-title":"Visual evoked potentials in patients after methanol poisoning","volume":"29","author":"Urban","year":"2016","journal-title":"Int. J. Occup. Med. Environ. Health"},{"issue":"12","key":"10.1016\/j.msard.2024.105850_bib0032","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1136\/jnnp-2021-326164","article-title":"Multiple sclerosis: structural and functional integrity of the visual system following alemtuzumab therapy","volume":"92","author":"Wang","year":"2021","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"9","key":"10.1016\/j.msard.2024.105850_bib0033","doi-asserted-by":"crossref","first-page":"6911","DOI":"10.1167\/iovs.11-7434","article-title":"Latency delay of visual evoked potential is a real measurement of demyelination in a rat model of optic neuritis","volume":"52","author":"You","year":"2011","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"7","key":"10.1016\/j.msard.2024.105850_bib0034","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1167\/iovs.12-9843","article-title":"Axonal loss in a rat model of optic neuritis is closely correlated with visual evoked potential amplitudes using electroencephalogram-based scaling","volume":"53","author":"You","year":"2012","journal-title":"Invest. Ophthalmol. Vis. Sci."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824004279?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824004279?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T04:29:53Z","timestamp":1732336193000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034824004279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":34,"alternative-id":["S2211034824004279"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2024.105850","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of disease-modifying therapies on remyelination in multiple sclerosis; evaluation via visual evoked potential test","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2024.105850","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105850"}}